The latest from DTC Perspectives
Glory Days Over?
Friday, 08 August 2008, 06:00 AM
Jim Edwards, who used to blog about advertising at Brandweek, is back writing his own blog. His July 29 th blog was titled “DTC Pharma Marketing's Glory Days Are Behind Us.” His rationale is that the lack of new drugs is the chief cause. He cites flat spending recently after significant increases a year ago as the evidence.
I would agree DTC spending, like all big pharma spending, is under pressure. Detail forces have been cut, manufacturing centers have been consolidated and headquarters staffs are being reduced to protect profits. DTC is certainly not immune from cuts.
To say the days of big spending are over is a premature conclusion. The number of brands spending more than $50 million on DTC is actually up versus last year. Most new brands are using it still. Mr. Edwards said television will be the chief casualty of the cuts, with other media keeping their budgets. He says “the days when primetime was filled with drug ads is going to fade from memory.” Of course if massive cuts are going to be made in future DTC budgets, television will be the biggest loser since that is where 60% is being spent.
Pundits have been confidently predicting the end of mass media DTC for years. They will be right one day as on demand viewing takes over. To date, there is no evidence of a major shift. DTC spending may be down 3-5% this year. That reflects current economic conditions and I do not consider that conclusive or that the glory days are over. If we see consistent 10% declines over several years, then we can say there is a permanent decline.
DTC mass media will be used as long as it is legal and it delivers a good ROI. The online, point of care and direct media will grow nicely as brands strive to target their spending and get stronger ROI. The issue with spending 100% on targeted media is finding ways to get the same scale as mass media.
The glory days may be waning, but there will be plenty of years left in sub-glory mode. We will see if Jim is right as the actual numbers come in for 2008. My bet is on a modest decline, not an end to DTC as we know it.
Related articles
A Powerful and Independent FDA
The Wall Street Journal reported on 7/30 that there is growing sentiment in Congress to drastically reform the FDA so it has fewer ties with the industries it
AstraZeneca Study Shows Value of Personal Interaction in Discount Program
An AstraZeneca company survey has found that 1/3 of its patients who utilize their AZ&Me prescription drug savings program are driven by doctors and pharmacists. Based
Blogspectives - Issue 4
Cliff Mintz in BioJobBlog (July 12) says pharma has discovered You Tube in a big way. He says many drug companies are using it to post ads, educational videos and
DTC Always On the Bubble
One of the common concerns of DTC marketers is the constant need to justify DTC spending to their management. After more than a decade of use, DTC is still apparently
Branded Websites Are The Most Effective Online Marketing Tactic For Pharmaceutical Marketers, comScore Study Finds
comScore, Inc., in conjunction with pharmaceutical marketing consultancy Evolution Road, today released results from the second annual study: e-Marketing Effectiveness
DTC and You
DTC in the Era of Consumer Choice
Register Now for this year's Fall Conference, focusing
on how DTC marketing must change in the face
of ever-increasing consumer pressures.
FREE Subscription to our Magazine
Start a free subscription now to the industry's leading
publication focused soley on DTC marketing,
DTC Perspectives Magazine is published quarterly.
Subscribe to DTC Insights
The DTC Marketer's Executive Brief - DTC INSIGHTS
takes all the information and data pertinent to DTC
and analyzes it for a busy pharma marketer.
Subscribe to Bob Ehrlich’s newsletter
A weekly blog column from DTCPI CEO Bob Ehrlich
that reflects his observations on key trends affecting
our industry.
| ABOUT SSL CERTIFICATES |

